Mysteries of TGF-β paradox in benign and malignant cells

Qiang Zhang, Nengwang Yu, Chung Lee*

*Corresponding author for this work

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

TGF-β regulates a wide range of biological functions including embryonic development, wound healing, organogenesis, immune modulation, and cancer progression. Interestingly, TGF-β is known to inhibit cell growth in benign cells but promote progression in cancer cells; this phenomenon is known as TGF-β paradox. To date, the mechanism of this paradox still remains a scientific mystery. In this review, we present our experience, along with the literature, in an attempt to answer this mystery. First, we observed that, on TGF-β engagement, there is a differential activation of Erk between benign and cancer cells. Since activated Erk is a major mediator in tumor progression and metastasis, a differentially activated Erk represents the answer to this mystery. Second, we identified a key player, PP2A-B56α, which is differentially recruited by the activated type I TGF-β receptor (TBRI) in benign and tumor cells, resulting in differential Erk activation. Finally, TGF-β stimulation leads to suppressed TBRs in tumor cells but not in benign cells. This differentially suppressed TBRs triggers differential recruitment of PP2A-B56α and, thus, differential activation of Erk. The above three events explain the mysteries of TGF-β paradox. Understanding the mechanism of TGF-β paradox will help us to predict indolent from aggressive cancers and develop novel anti-cancer strategies.

Original languageEnglish (US)
Article number94
JournalFrontiers in Oncology
Volume4 MAY
DOIs
StatePublished - Jan 1 2014

Fingerprint

Neoplasms
Organogenesis
Wound Healing
Embryonic Development
Neoplasm Metastasis
Growth

Keywords

  • Erk activation
  • PP2A recruitment
  • Positive feedback
  • Smad activation
  • TGF-β auto-induction
  • TGF-β paradox
  • TGF-β receptors
  • negative feedback

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{43e47e8961734498b037961925cefd4e,
title = "Mysteries of TGF-β paradox in benign and malignant cells",
abstract = "TGF-β regulates a wide range of biological functions including embryonic development, wound healing, organogenesis, immune modulation, and cancer progression. Interestingly, TGF-β is known to inhibit cell growth in benign cells but promote progression in cancer cells; this phenomenon is known as TGF-β paradox. To date, the mechanism of this paradox still remains a scientific mystery. In this review, we present our experience, along with the literature, in an attempt to answer this mystery. First, we observed that, on TGF-β engagement, there is a differential activation of Erk between benign and cancer cells. Since activated Erk is a major mediator in tumor progression and metastasis, a differentially activated Erk represents the answer to this mystery. Second, we identified a key player, PP2A-B56α, which is differentially recruited by the activated type I TGF-β receptor (TBRI) in benign and tumor cells, resulting in differential Erk activation. Finally, TGF-β stimulation leads to suppressed TBRs in tumor cells but not in benign cells. This differentially suppressed TBRs triggers differential recruitment of PP2A-B56α and, thus, differential activation of Erk. The above three events explain the mysteries of TGF-β paradox. Understanding the mechanism of TGF-β paradox will help us to predict indolent from aggressive cancers and develop novel anti-cancer strategies.",
keywords = "Erk activation, PP2A recruitment, Positive feedback, Smad activation, TGF-β auto-induction, TGF-β paradox, TGF-β receptors, negative feedback",
author = "Qiang Zhang and Nengwang Yu and Chung Lee",
year = "2014",
month = "1",
day = "1",
doi = "10.3389/fonc.2014.00094",
language = "English (US)",
volume = "4 MAY",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

Mysteries of TGF-β paradox in benign and malignant cells. / Zhang, Qiang; Yu, Nengwang; Lee, Chung.

In: Frontiers in Oncology, Vol. 4 MAY, 94, 01.01.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mysteries of TGF-β paradox in benign and malignant cells

AU - Zhang, Qiang

AU - Yu, Nengwang

AU - Lee, Chung

PY - 2014/1/1

Y1 - 2014/1/1

N2 - TGF-β regulates a wide range of biological functions including embryonic development, wound healing, organogenesis, immune modulation, and cancer progression. Interestingly, TGF-β is known to inhibit cell growth in benign cells but promote progression in cancer cells; this phenomenon is known as TGF-β paradox. To date, the mechanism of this paradox still remains a scientific mystery. In this review, we present our experience, along with the literature, in an attempt to answer this mystery. First, we observed that, on TGF-β engagement, there is a differential activation of Erk between benign and cancer cells. Since activated Erk is a major mediator in tumor progression and metastasis, a differentially activated Erk represents the answer to this mystery. Second, we identified a key player, PP2A-B56α, which is differentially recruited by the activated type I TGF-β receptor (TBRI) in benign and tumor cells, resulting in differential Erk activation. Finally, TGF-β stimulation leads to suppressed TBRs in tumor cells but not in benign cells. This differentially suppressed TBRs triggers differential recruitment of PP2A-B56α and, thus, differential activation of Erk. The above three events explain the mysteries of TGF-β paradox. Understanding the mechanism of TGF-β paradox will help us to predict indolent from aggressive cancers and develop novel anti-cancer strategies.

AB - TGF-β regulates a wide range of biological functions including embryonic development, wound healing, organogenesis, immune modulation, and cancer progression. Interestingly, TGF-β is known to inhibit cell growth in benign cells but promote progression in cancer cells; this phenomenon is known as TGF-β paradox. To date, the mechanism of this paradox still remains a scientific mystery. In this review, we present our experience, along with the literature, in an attempt to answer this mystery. First, we observed that, on TGF-β engagement, there is a differential activation of Erk between benign and cancer cells. Since activated Erk is a major mediator in tumor progression and metastasis, a differentially activated Erk represents the answer to this mystery. Second, we identified a key player, PP2A-B56α, which is differentially recruited by the activated type I TGF-β receptor (TBRI) in benign and tumor cells, resulting in differential Erk activation. Finally, TGF-β stimulation leads to suppressed TBRs in tumor cells but not in benign cells. This differentially suppressed TBRs triggers differential recruitment of PP2A-B56α and, thus, differential activation of Erk. The above three events explain the mysteries of TGF-β paradox. Understanding the mechanism of TGF-β paradox will help us to predict indolent from aggressive cancers and develop novel anti-cancer strategies.

KW - Erk activation

KW - PP2A recruitment

KW - Positive feedback

KW - Smad activation

KW - TGF-β auto-induction

KW - TGF-β paradox

KW - TGF-β receptors

KW - negative feedback

UR - http://www.scopus.com/inward/record.url?scp=84904597693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904597693&partnerID=8YFLogxK

U2 - 10.3389/fonc.2014.00094

DO - 10.3389/fonc.2014.00094

M3 - Article

VL - 4 MAY

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - 94

ER -